Cell type-specific induction of ferroptosis to boost antitumor immunity

  • Oncoimmunology. 2023 Nov 20;12(1):2282252. doi: 10.1080/2162402X.2023.2282252.
Jiao Liu  1 ,  Jingbo Li  2 ,  Rui Kang  3 ,  Daolin Tang  3
Affiliations
  • 1. DAMP Lab, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
  • 2. Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, China.
  • 3. Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
PMID: 38126037 DOI: 10.1080/2162402X.2023.2282252
Abstract

Traditional Ferroptosis activators typically suppress antitumor immunity. Our discovery shows that N6F11, a small molecule compound, can selectively induce Ferroptosis by targeting TRIM25-mediated GPX4 degradation in Cancer cells while sparing immune cells. This breakthrough establishes a safe and effective strategy to enhance ferroptosis-driven antitumor immunity.

Keywords
Drug discovery; GPX4; TRIM25; ferroptosis; immunotherapy.
Products